Adial Pharmaceuticals, Inc. Stock or Unit Option Plan Expense
Adial Pharmaceuticals, Inc. (ADIL) reported Stock or Unit Option Plan Expense of $435.83 thousand for the 12-month period ending 2018-12-31, per its 10-K filed 2019-02-19.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:StockOptionPlanExpense · last filed 2019-02-19
- Adial Pharmaceuticals, Inc. stock or unit option plan expense for the quarter ending 2018-12-31 was $0.00.
- Adial Pharmaceuticals, Inc. stock or unit option plan expense for the quarter ending 2018-09-30 was -$131.41K.
- Adial Pharmaceuticals, Inc. stock or unit option plan expense for fiscal 2018 was $435.83K.
| Period end | Stock or Unit Option Plan Expense 3 month | Stock or Unit Option Plan Expense 6 month | Stock or Unit Option Plan Expense 9 month | Stock or Unit Option Plan Expense 12 month |
|---|---|---|---|---|
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-19 | -$131.41K derived: sum of 2 quarters · filed 2019-02-19 | $435.83K 10-K · filed 2019-02-19 | |
| 2018-09-30 | -$131.41K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-14 | $435.83K 10-Q · filed 2018-11-14 | ||
| 2018-06-30 | $567.24K 10-Q · filed 2018-09-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |